Close

FDA Anticipates Supply Chain Threat For Medical Devices

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...

Now that the dreaded COVID-19 pandemic has seen its end, FDA officials are forecasting a probable dearth when it comes to medical devices, remarking in a new health affairs article that the supply chain may get threatened now that mandatory reporting will no longer be required.

It is well to be noted that for the duration of PHE, medical device companies were asked to send a notification to the FDA for any kind of shortage. Apparently, under the CARES Act, the FDA Centre for Devices and Radiological Health (CDRH) had the power to make sure that the manufacturers issued 506J notifications pinpointing any probable disruptions in the supply chain.

Reporting supply chain issues, henceforth, is going to be voluntary, which means that the agency is most likely going to have an incomplete picture of potential shortages. As described by the officials from the FDA, this is indeed going to make it more challenging so as to create a kind of resilience when it comes to the supply chain.

During the course of the PHE, the patients as well as the healthcare providers were pretty much impacted by the medical device shortages that ranged from ventilators to test supplies as well as personal protective equipment. That said, the CDRH was able to take immediate action.

It is well to be noted that in February 2021, Uri, the winter storm shut down the oil and gas sector across Texas as well as Louisiana, which resulted in the stalling of fresh resin, which happens to be a raw material that is used in the development of numerous medical devices. It is estimated that over 30 manufacturers as well as 180 devices got impacted, although since it was alerted through the disruption, CDRH could work with the suppliers, manufacturers, and partners from the US government to make sure that the medical device sector was able to access resin.

All this led to the issuance of priority access letters as well as the use of the Defence Production Act, i.e., the priority ratings that are used for resins in important medical devices. This let the manufacturers get allocations of resin, which in turn helped the catheters, syringes, and other items being produced that make use of resin. Significantly, the FDA officials also said that the supply chain issues are not going away at the PHE end. The medical device supply chain happens to have susceptibilities that are inherent in risks that predate COVID-19 and are most definitely going to exist even long after it.

Weather remains one of the most recurrent as well as growing challenges to supply chains, such as hurricanes, storms, extreme heat, floods, etc. There are other probable triggers in the case of supply chain issues, such as regulatory pressures, conflicts of geopolitical nature, shortages of raw materials, shortages and disputes of labour, bottlenecks pertaining to transportation, and energy crises.

Apparently, all the above elements do contribute to the consistent threat related to medical device shortages to patient care and safety.

As per FDA officials, catching the earliest signs of supply chain disruption helps in the best protection, such as the development of risk management plans. Manufacturers happen to be well-equipped when it comes to creating such plans as per the FDA and should be asked to share the information with the CDRH by way of 506J notifications.

The officials added that the agency should not have to learn about critical device shortages from patients as well as clinicians because that way it may as well turn out to be very late.

Latest stories

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back